-
[Editor's note: In this issue we continue with the second part of Patti Grant's IP Newbie column that was featured in our September issue. As you may recall, she described an all too common situation: How various professionals in healthcare are expected to participate in activities beyond their original area of expertise. This expectation does not seem so much a direct consequence of the struggling economy as a reflection of the attempt by various specialties to move from "silos" to a team approach to problem solving, Grant noted, observing that "Patient safety will most likely be less precarious in this multi-disciplinary improvement environment, but it can come with hefty growing pains." Of course, as an IP Newbie, you're often the one growing.]
-
The Joint Commission targets central lineassociated bloodstream infections in its 2011 national patient safety goals, with NPSG.07.04.01 calling for hospitals to "implement evidence-based practices to prevent (CLABSIs)."
-
The needle is beginning to move. Four key healthcare associated infections (HAIs) are declining nationally as the result of unprecedented interest and action that includes everything from sweeping state and federal collaboratives to the outrage of individual patients.
-
The elements of performance for the CAUTI prevention safety goal are as follows:
-
With the increasing reliance on computer tools and electronic records, infection preventionists may reasonably assume patients flagged for isolation on admission end up under the appropriate precautions.
-
HIV/AIDS mortality data highlight disparities between states, suggesting differences in HIV treatment and care, a new study shows.1
-
One obstacle to the success of the U.S. national HIV/AIDS strategy involves the accuracy of metrics used for monitoring HIV care, including late diagnoses and linkage to sustained care, a new study notes.
-
Thirty years after the world first became aware of a strange syndrome that caused young men to acquire rare diseases like Pneumocystis carinii pneumonia (PCP) and Kaposi's Sarcoma, nations across the globe continue to battle against the HIV/AIDS epidemic.
-
Updates to the darunavir (Prezista®) package insert, specifically sections: 6 Adverse Reactions, 12.4 Microbiology, 14 Clinical Studies and were approved on Oct. 19, 2011, to include results from the 192-week safety, resistance and efficacy data from study TMC114-C211, "A randomized, controlled, open-label Phase 3 trial comparing darunavir/ritonavir 800/100 mg once daily versus lopinavir/ritonavir 800/200 mg per day (given as a twice daily or as a once daily regimen) in antiretroviral treatment-naïve HIV-1-infected adult subjects."
-
The American Medical Association recently voted to support amending a federal law that bars clinical research of HIV-infected organ donation, as a potentially lifesaving measure for people living with HIV infection.
